Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Venous Thromboembolism 3Venous Thrombosis 2Thromboembolism 2Ovarian Neoplasms 2Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombosis 1Sarcoma 1Pulmonary Embolism 1Postoperative Complications 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 141Ifosfamide 85Radiotherapy 80Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 39Etoposide 39Docetaxel 39Vincristine 37Cisplatin 35Trabectedin 32Nivolumab 32Irinotecan 26Magnetic Resonance Spectroscopy 25Carboplatin 25Temozolomide 23Ipilimumab 22Bevacizumab 20Radiation 19Granulocyte Colony-Stimulating Factor 18Surgical Procedures, Operative 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17Biopsy 17eribulin 16Specimen Handling 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sarcoma × Fondaparinux × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡